OFFICIAL STATEMENTS

Press releases

28 May 2026

Breakthrough HER2 Imaging Technology Poised to Transform Cancer Diagnosis and Treatment

26 September 2023

Successful EUR 3 million financing round allows ABSCINT to start Phase II Clinical Trials

20 February 2023

ABSCINT and the VUB announce a Notice of Allowance for their U.S. Patent covering diagnostic applications of its single-domain antibody labelled with radioisotopes for PET/CT imaging of HER2 cancer lesions

5 December 2022

ABSCINT closed a new financing round to pursue development of single-domain antibody-based diagnostics

Our solution is available

Experience the future of diagnostics with ABSCINT. Illuminate HER2 expression for transformative precision in breast cancer and beyond.

Please note that the 68Ga-HER2 tracer has not yet received a marketing authorization in any jurisdiction.

Get Our Solution Today

What we do

Who we are

© 2026 ABSCINT

website by sixtyeight.studio

website by sixtyeight